Kang Stem Biotech Co., Ltd. has completed an IPO in the amount of KRW 12.00 billion.

Kang Stem Biotech Co., LTD is a Korea-based company mainly engaged in the development of pharmaceutical products. The Company's product portfolio consists of stem cell therapy products including Furestem-AD which used for treating atopic dermatitis, Furestem-RA which used for treating rheumatoid arthritis, Furestem-CD which used for treating crohn’s disease, stem cell conditioned medias which used as raw materials of cosmetics including umbilical cord blood-derived stem cell conditioned medias (USC-CMs) and others and stem cell culture medias including KSB-3 Complete Kit and others. The Company distributes its products within domestic market and to overseas markets.